At REMEDi4ALL, we are excited to highlight a new funding opportunity that looks to accelerating the integration of AI and data-driven approaches into drug repurposing.
Cures Within Reach has launched a Request for Proposals (RFP) to support Phase I/IIA clinical trials that validate AI-driven drug repurposing hypotheses. This is a unique opportunity for researchers to translate computational insights into real-world treatments, faster and more efficiently.
What is being funded?
- Investigator-initiated clinical trials in any disease area
- Projects using already approved drugs, biologics, or eligible cellular/gene therapies
- Trials led by principal investigators from nonprofit academic or research institutions worldwide
- Submissions must include AI model data as part of the required preclinical evidence
This opportunity, announced by Cures Within Reach CEO Barbara Goodmann at #iDR25, the international drug repurposing conference, could be a fit for members of the #iDR25 community with active projects which are harnessing the power of AI to unlock new therapeutic uses for existing medicines. Bridging the gap between computational drug discovery and clinical validation through new funding opportunities has the potential to transform the drug repurposing landscape and has the bring more treatments to more patients, faster.
“Our clinical trial funding program will empower clinicians anywhere to leverage sophisticated AI models for identifying and validating promising drug repurposing opportunities. By supporting the validation trials of these AI-generated drug-disease matches by researchers worldwide, we are removing barriers that have historically slowed medical progress.”
Barbara Goodman, CEO at Cures Within Reach
Learn more and apply for the Funding Opportunity at the Cures Within Reach website before 25 August 2025 .
